Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Expanding US operations to address the increased demand for API development and manufacturing
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
Subscribe To Our Newsletter & Stay Updated
